Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Galzus Research
2.17K Followers

Summary

  • Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer.
  • Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease.
  • The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.

Domino concept idea of business risk, strategy and planning

Jordan Lye/Moment via Getty Images

Topline Summary

Atara Biotherapeutics (NASDAQ:ATRA) is a commercial-stage biotech focused on the development and commercialization of cell therapies for patients with Epstein-Barr virus infection associated diseases and cancer. While they had a prominent trial

This article was written by

2.17K Followers
I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ATRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ATRA

Related Stocks

SymbolLast Price% Chg
ATRA
--